KennametalNYSE: KMT

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass.

PITTSBURGH , Nov. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is proud to announce that it has been recognized as one of Caterpillar Inc's top indirect suppliers in 2024. This prestigious recognition reflects Kennametal's continued dedication to delivering innovative solutions, productivity improvements and outstanding customer and applications engineering support.

Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide if Revumenib should be approved for the treatment of relapsed/refractory KMT2Ar Acute leukemia patients. The global acute myeloid leukemia market is expected to reach $5.86 billion by 2030; About 10% of patients have KMT2Ar AML and then 30% have mNPM1 AML.

PITTSBURGH , Nov. 12, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the UBS Global Industrials and Transportation Conference in Manalapan, Florida. Details of the conference are as follows:             When:      Tuesday, December 3, 2024             Attendees: Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.

KMT's fiscal first-quarter 2025 revenues decrease 2% due to the lackluster performance of the Metal Cutting segment.

The headline numbers for Kennametal (KMT) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kennametal (KMT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago.

Strong cash from operations of $46 million compared to $26 million in the prior year; free operating cash flow of $21 million compared to negative $3 million in the prior year Earnings per diluted share (EPS) of $0.28 and adjusted EPS of $0.29 Returned approximately $31 million to shareholders; $15 million in share repurchases and $16 million in dividends PITTSBURGH , Nov. 6, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today reported results for its fiscal 2025 first quarter ended September 30, 2024, with sales of $482 million compared to $492 million in the prior year quarter, and earnings per diluted share (EPS) of $0.28 compared to $0.37 in the prior year quarter. The current quarter pre-tax results include a net benefit of $4 million, consisting of insurance proceeds offset by additional costs, related to the tornado that struck the Company's Rogers, Arkansas facility late in fiscal 2024, as well as certain tax-related items amounting to a benefit of approximately $3 million.

One New Offering Specific to Small Parts Machining & Medical Applications  PITTSBURGH , Oct. 25, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is expanding its turning portfolio with the introduction of new inserts and cutting tools that significantly broadens its machining capabilities in the small parts and medical machining space. The three new products –TopSwiss™ Turning Inserts and Micro Boring Solid (MBS) tooling, and KCU25B Turning Inserts – are designed to improve output, enhance component quality, reduce errors and help customers achieve accurate and clean results.